{"nctId":"NCT01850641","briefTitle":"A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia","startDateStruct":{"date":"2013-04-29","type":"ACTUAL"},"conditions":["Hemodialysis","Hyperphosphatemia"],"count":35,"armGroups":[{"label":"PA21","type":"EXPERIMENTAL","interventionNames":["Drug: PA21"]}],"interventions":[{"name":"PA21","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Receiving stable maintenance hemodialysis 3 times a week\n* Dialysis patients with hyperphosphatemia\n\nExclusion Criteria:\n\n* Patients having history of a pronounced brain / cardiovascular disorder\n* Patients having severe gastrointestinal disorders\n* Patients having severe hepatic disorders","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Adverse Events","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Phosphorus Concentrations at End of Treatment (Actual Measured Value)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.89","spread":"1.14"}]}]}]},{"type":"SECONDARY","title":"Corrected Serum Calcium Concentrations at End of Treatment (Actual Measured Value)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.52","spread":"0.88"}]}]}]},{"type":"SECONDARY","title":"Serum Intact-PTH Concentrations at End of Treatment (Actual Measured Value)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"177.9","spread":"146.4"}]}]}]},{"type":"SECONDARY","title":"Serum Ferritin Concentrations at End of Treatment (Actual Measured Value)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.8","spread":null}]}]}]},{"type":"SECONDARY","title":"TSAT at End of Treatment (Actual Measured Value)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.72","spread":"8.27"}]}]}]},{"type":"SECONDARY","title":"Hb Concentrations at End of Treatment (Actual Measured Value)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.22","spread":"1.19"}]}]}]},{"type":"SECONDARY","title":"Constipation Condition","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]},{"measurements":[{"groupId":"OG000","value":"14","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null}]},{"measurements":[{"groupId":"OG000","value":"5","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Satisfaction With Bowel Movement","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null}]},{"measurements":[{"groupId":"OG000","value":"8","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null}]},{"measurements":[{"groupId":"OG000","value":"5","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":35},"commonTop":["Diarrhoea","Nasopharyngitis","Dermatitis contact","Haemorrhage subcutaneous","Back pain"]}}}